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In conformational diseases, native protein con-
formers convert to pathological intermediates that
polymerize. Structural characterization of these key
intermediates is challenging. They are unstable and
minimally populated in dynamic equilibria that may
be perturbed by many analytical techniques. We
have characterized a forme fruste deficiency variant
of a1-antitrypsin (Lys154Asn) that forms polymers
recapitulating the conformer-specific neo-epitope
observed in polymers that form in vivo. Lys154Asn
a1-antitrypsin populates an intermediate ensemble
along the polymerization pathway at physiological
temperatures. Nuclear magnetic resonance spec-
troscopy was used to report the structural and
dynamic changes associated with this. Our data
highlight an interaction network likely to regulate
conformational change and do not support the re-
cent contention that the disease-relevant interme-
diate is substantially unfolded. Conformational
disease intermediates may best be defined using
powerful but minimally perturbing techniques, mild
disease mutants, and physiological conditions.
INTRODUCTION
The conformational diseases are characterized by conformational
transitions in mutant proteins that allow multimerization and aber-
rant protein deposition. They include Alzheimer’s disease and
Lewy body dementia, the prion encephalopathies, systemic
amyloidosis, and the serpinopathies (Lomas and Carrell, 2002).
The serpinopathies result from the polymerization of mutants of
members of the serine protease inhibitor or serpin superfamily of
proteins (Gooptu and Lomas, 2009). The archetype of the serpino-
pathies is a1-antitrypsin deficiency. a1-antitrypsin is synthesized
by hepatocytes (Laurell and Jeppsson, 1975) and released into
the circulation, where it protects the lung from the actions of
neutrophil elastase (Gooptu et al., 2009a). Severe a1-antitrypsin504 Structure 20, 504–512, March 7, 2012 ª2012 Elsevier Ltd All righdeficiency is found in 1:2000 individuals of North European
descent (Blanco et al., 2001) and typically results from homozy-
gosity for the Z allele (Glu342Lys). The Z mutation causes
a1-antitrypsin to adopt an intermediate conformation and rapidly
polymerize (Figure 1A; Lomas et al., 1992). Polymers accumulate
within the endoplasmic reticulum of hepatocytes in association
with neonatal hepatitis, cirrhosis, and hepatocellular carcinoma.
Concomitant deficiency of circulating a1-antitrypsin predisposes
to severe, early onset emphysema (Gooptu and Lomas, 2008).
Previousdata suggest that serpinpolymers are formedby inter-
molecular linkage of the reactive center loop of onemolecule with
b sheet A of another (Dunstone et al., 2000; Gooptu et al., 2000;
Huntington et al., 1999; Lomas et al., 1992; Schulze et al., 1990).
However, a recent model suggests that the polymer is linked by
a more extensive domain swap involving both the reactive center
loop and strand 5 of b sheet A (Krishnan and Gierasch, 2011; Ya-
masaki et al., 2008). The controversy may be partly explained by
our recent finding that structurally distinct polymers are favored
by different conditions used to induce polymerization in vitro
(Ekeowaet al., 2010). Resolving these issues at a residue-specific
level is important for targeting drug design against the patholog-
ical polymerizationofa1-antitrypsindeficiency.Wehave therefore
used nuclear magnetic resonance (NMR) spectroscopy and
adeficiency-associatedandpolymerogenica1-antitrypsin variant
to characterize structural and dynamic changes associated with
population of the pathological intermediate state.
RESULTS
Detection of a1-AntitrypsinQueen’s
A mutation that, to our knowledge, has not previously been
described was detected in an individual whose circulating
a1-antitrypsin levels (median value 0.6 mg/ml; normal range
1.5–3.5mg/ml) were between those expected of a Z homozygote
and an MZ heterozygote. Genotyping revealed a compound
heterozygote for the Z allele and a Lys154Asn variant that we
have named a1-antitrypsinQueen’s.
Population of the Pathological Intermediate
Recombinant Lys154Asn a1-antitrypsin was characterized
biochemically and biophysically (Figure S1, available online;ts reserved
Figure 1. Pathological Polymerization of Lys154Asn a1-Antitrypsin
(A) Polymerisation pathway from native conformer (mutation site circled).
(B)7.5%(w/v)nativePAGE;polymerizationofwild-typeandLys154Asna1-antitrypsin (0.5mg/mlprotein [pH7.4]) invitroover12daysat37
Cand42C.Polymerization
is reported by loss of the monomeric band and the appearance of aggregated protein. (Right) Polymers formed by 30 min incubation between 40C and 50C of
nonglycosylated wild-type (blue) and Lys154Asn (red) a1-antitrypsin are detected by 2C1 mAb ELISA (Z a1-antitrypsin polymer calibrated; Miranda et al., 2010).
Differences between wild-type and mutant are significant (p < 0.05 to p < 0.005) for all temperatures. The increase in signal relative to starting material reaches
significance for Lys154Asn a1-antitrypsin for incubations at 47.5 (p < 0.05) and 50 (p < 0.005)
C. Data aremean ± standard deviation (error bars) of three experiments.
(C) (Left) Thermal denaturation CD spectroscopy (left; mean ellipticity at 222 nm, n = 10) for wild-type (blue) and Lys154Asn (red) a1-antitrypsin. (Right) Arrival
times and collision cross-section (CCS) values calculated by IM-MS for wild-type (blue) and Lys154Asn a1-antitrypsin indicated a 7.8% increase in CCS in
Lys154Asn relative to wild-type a1-antitrypsin at 39
C (no difference at 20C and 34C). Data are mean ± standard deviation (error bars) of three experiments.
See also Figure S1.
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Pathological Solution Behavior of a1-AntitrypsinFigures 1B and 1C). The variant had 64% of the functional
activity of wild-type a1-antitrypsin (i.e., 1.6-fold greater stoichi-
ometry of inhibition [SI]) with an apparent association rate
constant (kapp’) with bovine a-chymotrypsin of 5.5 (+/1.1) 3
104 M-1s-1 (n = 3). When corrected for the increase in SI, the
association rate constant (kapp) for Lys154Asn a1-antitrypsin
was 1.3 3 105 M-1s-1, an order of magnitude lower than the
wild-type control (1.16 3 106 M-1s-1). Sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) confirmed
increased substrate-like behavior in Lys154Asn a1-antitrypsin
relative to the wild-type (Figure S1C).
The Queen’s variant formed polymers under physiological
conditions (Figure 1B). This was slow at 37C, and more rapid
at 42C and higher temperatures. The general pathological rele-
vance of these polymers was demonstrated by the presence of
the 2C1 neo-epitope that is specific for polymers associated
with disease (Miranda et al., 2010; Figure 1B, right).
Polymer formation occurs via population of an intermediate
state (Dafforn et al., 1999). We therefore studied intermediate
formation by Lys154Asn a1-antitrypsin. The variant populated
intermediate states more readily than wild-type a1-antitrypsin
in urea-induced and thermal denaturing conditions (Figure S1A;
Figure 1C). Since we had established the disease relevance of
the polymerogenic intermediate at temperatures in the physio-
logical range, we focused on structural changes induced by
incubation in these conditions. CD spectroscopy studies
(Figures 1C and S1D) indicated that the mutant fold underwent
a subtle structural transition between 35C and 45C before
more dramatic transition between 50C and 60C. Increasing
concentration did not affect the first transition but caused
the second transition to commence at a lower temperature.
Wild-type a1-antitrypsin remained stable to 60
C and underwent
a sharp unfolding transition at higher temperatures, consistent
with previous studies (Gooptu et al., 2009b; Parfrey et al.,
2003). Increasing concentration cold-shifted the second half of
the transition but did not affect its initial phase (Figure S1D).
Increasing protein concentration 2.5-fold (0.4 to 1.0 mg/ml)
reduced the midpoint of the overall transition for wild-type
a1-antitrypsin by 1.5C and that of Lys154Asn a1-antitrypsin
by1.0C. The profiles of the first part of the transition observed
for wild-type a1-antitrypsin and the first transition observed
for Lys154Asn a1-antitrypsin are both concentration-indepen-
dent. Therefore, this likely reports upon structural change within
the molecule. The subsequent transition is concentration-
dependent. It therefore likely reports, to some degree, upon
polymerization of a species populated during the first phase.
Polymerogenic intermediate formation in a1-antitrypsin has
been previously studied by ANS fluorescence. ANS fluoresces
strongly upon binding to regions in which both polar and hydro-
phobic motifs are exposed to solvent and so binds to interme-
diate states, rather than fully folded or unfolded polypeptides.
The ability of the Queen’s variant of a1-antitrypsin to bind ANS
was therefore assessed (Figure S1E). Lys154Asn a1-antitrypsin
showed hyperfluorescence compared with the wild-type protein
at 25C. This was unexpected, since assays directly reporting
structural information (CD spectroscopy, intrinsic fluorescence,
and NMR spectroscopy) strongly indicated that both proteins
were similarly well-folded and stable at this temperature. These
observations of Lys154Asn a1-antitrypsin behavior are similar to506 Structure 20, 504–512, March 7, 2012 ª2012 Elsevier Ltd All righthose described for Z a1-antitrypsin (Knaupp et al., 2010). More-
over, incubating Lys154Asn a1-antitrypsin with ANS for longer
resulted in even greater hyperfluorescence, whereas increasing
temperature to 37C did not enhance this further (Figure S1E).
Wild-type a1-antitrypsin showed no change in ANS fluorescence
at either temperature or upon prolonged incubation. These data
indicate that for a1-antitrypsin variants in which conversion to
the polymerogenic intermediate in solution is facile, ANS binding
stabilizes the intermediate state sufficiently to skew the position
of the native-intermediate equilibrium to the right. For Lys154Asn
a1-antitrypsin, this effect is so significant that it outweighs any
effect of temperature change between 25C and 37C. This
supports our general view that the degree to which assays
perturb solution equilibria must be considered when studying
intermediate formation.
We hypothesized that ion-mobility mass spectrometry (IM-MS)
might have sufficient sensitivity to detect population of the inter-
mediate while minimally perturbing the solution equilibrium. At
20Cand34C,monomericLys154Asna1-antitrypsinwas indistin-
guishable from thewild-type protein by IM-MS. However, at 39C,
there was a 7.8% increase in the collision cross-section (CCS) of
monomeric Lys154Asn a1-antitrypsin relative to the wild-type
protein in keeping with population of an intermediate state (Fig-
ure 1C). The CCS of the intermediate state has been calculated
as 18% greater than the native state, so a 7.8% increase in
CCS is consistent with substantial population (40%) of the inter-
mediate state in equilibrium at physiological temperatures.
NMR Spectroscopic Characterization of a1-Antitrypsin
Solution Behavior and Mutation Effects
We have observed and assigned backbone resonances for
almost all residues in wild-type a1-antitrypsin in a series of
NMR experiments (Biological Magnetic Resonance Bank entry
17804; Nyon et al., 2011), allowing us to analyze its solution
behavior (Figures 2 and S2). Chemical shift index analysis (Ber-
janskii and Wishart, 2006) was performed for Ca backbone
bond signals alone or in conjunction with side-chain signals (Fig-
ure S2A). This method did not use any crystallographically
derived predictions, so it permitted residue-specific comparison
of the secondary structure behavior of the protein directly
observed in solution with that observed crystallographically.
Although most of the secondary structure behavior of individual
residues was conserved between solution and the crystal lattice
conditions, b sheet C showed considerable lability in solution.
The solution behavior of helices C and I was reported as a-helical
by Ca backbone bond signals. However, when side-chain sig-
nals were also considered, these reported random coil behavior.
Such differences may indicate that these motifs also displayed
some lability in solution (Figure S2A).
Two-dimensional (2D) NMR spectroscopy of 15N-labeled
Lys154Asn a1-antitrypsin was then performed (Figure 2). At
25C the well-dispersed regions of the spectrum contained a
similar number (148) of cross-peaks to the number seen for the
wild-type protein (152), and mean cross-peak intensities were
similar for both proteins. A subset of 123 residues could be
confidently assigned in the well-dispersed region of the 1H-15N
TROSY-HSQC spectrum of Lys154Asn a1-antitrypsin. Overall
peak integrals in the central region were also similar between
the spectra for wild-type and Lys154Asn a1-antitrypsints reserved
Figure 2. 1H-15N TROSY-HSQC Spectrum of Wild-Type and Lys154Asn a1-Antitrypsin
Zoom (right) illustrates examples of reporter residues (wild-type, black; Lys154Asn, red).
See also Figure S2.
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Pathological Solution Behavior of a1-Antitrypsin(Figure S2B). Nevertheless intensity and chemical shift differ-
enceswere induced by the presence of themutation in the native
state of the protein (Figure S2C). The degree of variation reported
by intensity and chemical shift in the observed residues corre-
lated closely. The magnitude of changes are shown by heatmap
coloring of spheres mapped to the crystal structure and demon-
strate the mutation most affects residues around the F-helix,
strands 1–3 of b sheet A, and the reactive loop. In particular,
the spectral effects were most dramatic on residues around
hF and s3A, where the chemical shift changes were too great
to allow their confident assignment in the mutant protein (Fig-
ure S2C, black spheres).
NMR Spectral Changes and Polymerogenicity
Our principal aimwas to assess changes in a1-antitrypsin associ-
ated with population of the disease-relevant intermediate
state. Native state behavior was defined as that observed for
wild-type a1-antitrypsin at the temperatures studied in which no
polymerization was observed. At 37C, slow, irreversible, and
linear loss of the observable, monomeric sample due to
polymerization was observed in Lys154Asn but not the wild-
type a1-antitrypsin. The linearity indicated a constant rate of
polymer formationandhence that thepopulationof thepolymero-
genic intermediate was also constant, that is, the solution was
in pseudo-equilibrium. 1H-15N TROSY-HSQC spectra reported
residue-specific structural and dynamic changes in Lys154Asn
a1-antitrypsin by nonuniform intensity change in assigned
cross-peaks relative to wild-type a1-antitrypsin (Figure 3A).
Values are scaled for monomer concentration; they take into
account changes observed between wild-type and mutant
protein at 25C in the absence of polymerization and changes
observed in wild-type a1-antitrypsin between 25
C and 37C.
They therefore report differential changes in Lys154Asn a1-anti-
trypsin associated with population of the polymerogenic state.Structure 20,Most reporter cross-peaks signaled minimal change in
Lys154Asn a1-antitrypsin at 37
C (Figure 3B). Those in strand 5
in b sheet A, helix I, and the connecting linker strongly preserved
intensity (Figure 3C). NMR intensity data are highly sensitive
reporters of changes in structure and dynamics, so relatively
large changesmay be induced by quite small changes in solution
behavior. Nevertheless, residues reporting the most dramatic
intensity change in the polymerogenic ensemble notably occur
in regions previously linked with conformational change (upper
s3A, upper hF, underlying the upper s4A site, and hA; Cabrita
et al., 2004; Mahadeva et al., 1999; Zhou et al., 2003).
A further 12 distinct cross-peaks (signal:noise 11.5) were
observed in the well-dispersed region of the spectrum in
Lys154Asn but not the wild-type a1-antitrypsin at 37
C (Fig-
ure S3A). The new cross-peaks disappeared on cooling and so
may represent residues within a nonnative monomeric state,
rather than polymers, since these did not dissociate (and would
predictably give peaks of very low intensity). If so, these data
support a process of native-non-native monomeric conforma-
tional exchange that is slow (Rms) by NMR timescales, consis-
tent with previous data (Dafforn et al., 1999).
The mutation will mildly perturb local electrostatic interactions
involving Lys154 (Figure S3B). Its effects on resonances of
nearby residues were too great to dissect by cross-peak anal-
ysis. We therefore studied a eukaryotic cell model of disease
(Gooptu et al., 2009b) by mutagenesis. These clarified that the
hydrogen bond of Lys154 (F-helix) with the main-chain carbonyl
oxygen of Lys174 (neighboring linker) regulated against polymer
formation (Figure S3B).
The residue-specific changes caused by the Lys154Asnmuta-
tion differed markedly from those observed in urea conditions
causing a similar degree of polymerization (1.5 M; Figure S3C).
Both patterns differ from that indicated by studies in guanidine
or low pH conditions (Krishnan and Gierasch, 2011; Yamasaki504–512, March 7, 2012 ª2012 Elsevier Ltd All rights reserved 507
Figure 3. Population of the Intermediate by Lys154Asn a1-Antitrypsin under Physiological Conditions
(A) Differential change in intensity for reporter cross-peaks in the 1H-15N TROSY-HSQCof Lys154Asn a1-antitrypsin at 37
C. Intensities are scaled relative to the wild-
type protein at the same temperature and the intensities observed for Lys154Asn a1-antitrypsin relative to the wild-type at 25
C [(IK154N,37/Iwt,37)/(IK154N,25/Iwt,25)].
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Pathological Solution Behavior of a1-Antitrypsinet al., 2008). Thus, the polymerogenic monomer ensemble to
which this mild deficiency mutation reduces the energetic
barrier, differs structurally and/or dynamically from polymero-
genic ensembles induced by other conditions. The resultant
polymers are also structurally distinct (Ekeowa et al., 2010).
DISCUSSION
Studying key native to intermediate transitions can elucidate
mechanisms of the conformational diseases and aid targeting
of novel therapeutic strategies. However, the intrinsic tendency
of intermediates to adopt more stable, polydisperse, and
multimeric conformations renders this inherently challenging.
Moreover, structurally distinct serpin polymers are induced by
chemical denaturants compared to pathological mutations or
heating (Ekeowa et al., 2010). Techniques that can perturb
equilibria by stabilizing particular structural endpoints (e.g.,
selective labeling, proteolysis, and/or peptide binding) may
also skew characterization of intermediate ensembles in confor-
mational diseases. We have therefore undertaken the residue-
specific study of a forme fruste disease mutant in solution, under
physiological conditions, using minimally perturbing techniques.
This is arguably the best strategy for studying intermediate
states relevant to conformational diseases.
Lys154Asn a1-antitrypsin populates a polymerogenic interme-
diate state at 37C. Polymers formed from Lys154 mutants
recapitulate the pathognomic 2C1 neo-epitope. Polymerization
of Lys154Asn a1-antitrypsin is therefore a good structural model
for the pathological polymerization in vivo of more common and
severe variants, such as Z a1-antitrypsin. Serendipitously, poly-
merization occurs slowly enough to allow the study of the
solution behavior of a1-antitrypsin when the pathological inter-
mediate state is populated. We have overcome obstacles posed
by the molecule’s large size (45 kDa) to use NMR spectroscopy
and characterize residues that remain native-like or alter their
solution behavior in association with formation of the patholog-
ical intermediate. Our data are consistent with sufficient popula-
tion of the intermediate state in Lys154Asn a1-antitrypsin at
physiological temperatures to contribute to our observations.All intensities were scaled for concentration and 4,4-dimethyl-4-silapentane-1-sulf
observed in the datasets from which the values are derived, according to the formu"
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
IK154N;25
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where I is the intensity for data obtained fromwild-type (WT) or Lys154Asn (K154N) a
the observed standard deviation of peak intensities within each spectra.
(B) Relative intensities quantified in (A) mapped onto the subset of reporter resid
white; reductions, blue). Greatest change (maximally blue by RGB, residue 39) cor
intensity on the same scale. Ellipse: hA region reporting major change from nativ
(C) (Left) Intensity change and stability observed in b sheet A, hF, hI, and conne
parsimonious (center) and b-hairpin (right) linkage models of polymerisation for c
(D) (Left) Unlocking the clasp. Proposed scheme of polymerogenic intermediate f
through b sheet A (blue) and more distant motifs. The Lys154Asn mutation abol
region (I). Under physiological conditions this destabilization causes remodeling of
of s3A (III) facilitate lateral movement required to open the s4A site. Changes i
C-terminal residues of hA (V). Most of the residues within b sheet A remain within
only for residues in s5A but also for residues in hI and the connecting linker. (Right)
induced by the Gly117Phe mutation; Gooptu et al., 2009b) and destabilizing (red
See also Figure S3.
Structure 20,Most observed residues behave in a highly native-like way under
these conditions. Relative intensity values indicate preservation
of native-like signal after correcting for changes due to the
mutation at 25C and changes in protein tumbling and polymer-
ization at 37C. A value of 100%would therefore indicate entirely
native-like structural and dynamic behavior in a particular
residue. The mean relative intensity across the entire subset of
residues that could be analyzed in this way was 82%. It is there-
fore unlikely that the intermediate ensemble is substantially
unfolded as required for extensively domain-swapped models
of polymerization. Specifically, analysis of cross-peak intensities
supports high stability in the hI-s5A region proposed to unfold in
the b-hairpin model (Figure 3C). This is indicated by relative
intensities of 90% for the seven residues within this region
compared with the equivalent cross-peaks in the native state.
Similar preservation of native-like signal is indicated for the
core strands 4 and 5 of b sheet B (residues 370–388).
Larger changes (Figures 3A and 3B) may be due to a number
of differences in structural and/or dynamic behavior, so their
interpretation is complex. Nevertheless, the localization of the
greatest changes from wild-type native behavior is striking.
Such changes are reported by residues in regions associated
with remodeling during formation of the intermediate state in
parsimonious models of polymerization (Figure 3B, left panel,
circled: Thr165 at the top of hF, relative intensity 0.46, Phe189,
upper s4a, 0.31). The effects on these residues cannot be
simply explained by proximity to the mutation site, since they
lie further from it than many residues that report highly native-
like behavior. Residues reporting a major loss of relative intensi-
ties are also observed at the C-terminal end of hA (Figure 3B,
right panel ellipse: Arg39, relative intensity 0.11 and His 43,
0.33), even further from the mutation site. This corresponds to
the site of another polymerogenic a1-antitrypsin deficiency
mutation (Ile39Cys; Mahadeva et al., 1999). Mutations in nearby
serpin residues (Tyr38Ser, antithrombin; Leu41Pro, a1-antitryp-
sin) are also associated with deficiency and disease (Dafforn,
1999). Our data suggest that structural and/or dynamic changes
here are associated with formation of the pathological interme-
diate. The effects would be transmitted most directly to theonic acid (DSS) control intensity. Error bars are defined according to variability
laﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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responds to a relative intensity of 0.11. Increasing redness indicates increasing
e-like intensity.
cting linkers. Current structural models of polymerogenic intermediates in the
omparison (b strand 5A magenta; hI and connecting linker cyan).
ormation through propagation of conformational change from the mutation site
ishes a hydrogen bond between hF and the neighboring linker (clasp, purple)
the upper part of the clasp (II). Consequent structural changes in the upper part
n s3A are also transmitted via (IV) the shutter region and s6B (brown) to the
a native-like environment during formation of the intermediate. This is seen not
Factors stabilizing (blue, arrow denotes stabilizing displacement of clasp region
) the network of regulatory interactions.
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(Figure 3D), known hotspots for pathological, polymerogenic
mutations.
Taking together the data from biochemical, biophysical,
enzyme-linked immunosorbent assay (ELISA) and cell studies,
and previous observations (Bruce et al., 1994; Sharp et al.,
1999), we propose that the helix F and linker region constitutes
a ‘‘clasp’’ motif (Figure 3D, purple). This may seal a network of
interactions that regulate conformational change. Compromise
of the network is associated with formation of the pathological
intermediate.
Our data indicate that the methods used to induce interme-
diate formation when studying conformational diseases can be
major determinants of the structural distribution of intermediate
states within the solution ensemble. A recent study undertook
residue-specific labeling of single Cys mutants during early
guanidine denaturation. It supported extensive unfolding of
strands 5 and 6, as well as helices F and I (Krishnan and Gier-
asch, 2011). That pattern differs from our observations, both in
the presence of the Lys154Asn mutation at 37C and in low
concentrations of urea. The modulation of monomeric ensem-
bles to produce analogous but structurally distinct polymer
states is relevant to studies of other conformational diseases,
where chemical denaturants are commonly used in vitro to
induce multimerization. It may also explain the phenomenon of
strain specificity observed in conformational disorders, such as
prion diseases and amyloidoses.
We have demonstrated that NMR spectroscopy is optimal
for studying pathological intermediate formation in the serpino-
pathies, providing residue-specific detail without perturbing
dynamic solution equilibria. Comparison of wild-type a1-anti-
trypsin characteristics with those of mild deficiency variants
also powerfully dissects disease-relevant behavior. Such studies
appear timely, given the range of proposed polymerisation
models based upon data obtained using a range of more per-
turbing techniques. Further studies using different variants and
NMR modalities, for example, detailed dynamics studies, will
further characterize this contentious mechanism of pathological
conformational change to optimize drug design and so treat the
serpinopathies.EXPERIMENTAL PROCEDURES
Molecular Biology, Protein Purification, and Cell-Free
Characterization
Mutations were introduced into a1-antitrypsin cDNA within the pQE31 and/or
the pcDNA3.1 plasmids by polymerase chain reaction mutagenesis (Zhou
et al., 2001; Gooptu et al., 2009b). pQE31 plasmids containing cDNA encoding
hexahistidine-tagged, recombinant a1-antitrypsin were transfected into XL1
Blue Escherichia coli (Stratagene, Santa Clara, California, USA). The proteins
were expressed and purified as previously described (Parfrey et al., 2003).
They were characterized using SDS-, nondenaturing and transverse urea
gradient (TUG)-PAGE, circular dichroism (CD), intrinsic and 8-anilinonaphtha-
lene-1-sulfonate (ANS) fluorescence spectrometry and by enzyme inhibitory
activity and kinetics assays (Dafforn et al., 1999, 2004; James et al., 1999;
Stone and Hofsteenge, 1986).
Ion Mobility Mass Spectrometry
Samples were buffer exchanged into 100 mM ammonium acetate (pH 7.0),
desalted, and concentrated to a final concentration of 20 mM. Proteins were
introduced to the mass spectrometer by nano electrospray ionization. All510 Structure 20, 504–512, March 7, 2012 ª2012 Elsevier Ltd All righIM-MS experiments were performed in a hybrid quadrupole, orthogonal accel-
eration time-of-flight (oa-TOF) mass spectrometer equipped with a traveling
wave (T-Wave) ion mobility separation device (Synapt HDMS, Waters, Man-
chester, UK; Pringle et al., 2007). The source temperature was 40C, capillary
voltage optimized 1.0–1.2 kV, and cone voltage was 20 V. The pressure in the
T-Wave ion mobility cell was 0.55 mbar. The mobility gas was nitrogen.
T-Wave height and velocity were set at 10 V and 300 m/s, respectively. Arrival
time distributions were converted to collision cross-sections (CCS) by power
fit (Hilton et al., 2010; Thalassinos et al., 2009). The calibrant protein was
equine myoglobin (Sigma-Aldrich, Gillingham, UK). Data acquisition and pro-
cessing were carried out using MassLynx 4.1 software (Waters Corp., Milford,
MA, USA). Data are the mean (+/ SD) of three repeats.
Sample Preparation for NMR Spectroscopy
cDNA coding for hexahistidine-tagged a1-antitrypsin within a pQE31 plasmid
was transformed into strain BL21-Gold (DE3) E. coli (Stratagene). Cells
were cultured in M9 minimal media (in H2O or D2O) at 37
C with 1 g/l of
15NH4Cl (Spectra Stable Isotopes, Columbia, MD, USA) and 2 g/l of either
glucose or 13C-glucose (Sigma-Aldrich) as the sole nitrogen and carbon sour-
ces, respectively. Following induction of protein expression cells were grown
for 6 hr, rather than the 4 hr, period used with rich media. In all other respects
protein expression and purification was carried out as described above.
Samples were stored in 25 mM Na2HPO4 (pH 8.0), 50 mM NaCl, and 1 mM
ethylenediaminetetraacetic acid. Sample homogeneity was confirmed by
SDS-, nondenaturing and transverse urea gradient (TUG)-PAGE and by
assessment of inhibitory activity.
NMR Spectroscopy Conditions
NMR spectra used to compare wild-type and Lys154Asn a1-antitrypsin
were collected on uniformly 15N-labeled samples at 298 K, 175 mM on a Varian
UnityInova 600 MHz spectrometer with an HCN cryoprobe. Ten percent D2O/
1% 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) was added to concen-
trated a1-antitrypsin samples prior to NMR spectroscopy.
Backbone assignments were obtained from TROSY (Pervushin et al., 1997)
versions of HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB, and HN(CO)
CACB spectra (Eletsky et al., 2001; Salzmann et al., 1998), together with
a 3D NOESY-TROSY-15N HSQC spectrum (Zhu et al., 1999). 2H decoupling
(1 kHz WALTZ-16; Shaka et al., 1983) was applied in triple-resonance
experiments. Magnetization was transverse on CA or CB. Two-dimensional
TROSY-15N HSQC spectra for assignment. Wild-type and Lys154Asn a1-anti-
trypsin comparison spectra were recorded using single-transition-to-single-
transition polarization transfer and phase cycling for coherence order selection
(Rance et al., 1999; Zhu et al., 1999). Spectra were processed and analyzed
using nmrPipe (Delaglio et al., 1995) and CCPN (Fogh et al., 2002). All spectra
were referenced to DSS at 0.0 ppm, manually phased and baseline corrected.
Lys154Asn a1-antitrypsin spectra were analyzed by changes in cross-peak
intensity relative to the data on wild-type a1-antitrypsin (IK154N/Iwild-type) and
magnitude of chemical shift change (Dd). This was calculated asﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Dd1H
2
+

Dd15N=5
2q
;
where D1H was the change in the chemical shift along the 1H axis andD15N the
change in chemical shift along the 15N axis (parts per million [ppm]).
Cell Biological Characterization
The pcDNA3.1 plasmids containing wild-type and mutant a1-antitrypsins were
transiently transfected into COS-7 cells. The resulting protein expression was
characterized by western blot analyses of SDS- and nondenaturing PAGE of
intracellular material as previously described (Miranda et al., 2008, 2004).
Luciferase controls were used to confirm equivalent loading between samples.
The polymer load was quantified by ELISA using the polymer-specific 2C1
monoclonal antibody as the primary antibody (Miranda et al., 2010).SUPPLEMENTAL INFORMATION
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